Scholar Rock Holding (SRRK) Advances Apitegromab Review, Is 11% Undervalued Enough?

Scholar Rock Holding (SRRK) has drawn fresh attention after reporting second quarter 2026 results, alongside a detailed update on apitegromab’s regulatory path, including progress with the FDA and EMA and preparations for a possible U.S. launch.

See our latest analysis for Scholar Rock Holding.

The latest apitegromab update appears to have sharpened focus on Scholar Rock Holding, with the stock’s recent 7 day share price return of 15.42% and year to date share price return of 23.64% sitting alongside a very large 3 year total shareholder return. Together, these figures indicate that momentum has been building rather than fading.

If you are looking for more ways to act on this kind of biotech news, it can be useful to see what is happening across other healthcare related AI opportunities through the 43 healthcare AI stocks

The recent jump in Scholar Rock Holding shares sits against ongoing losses and a pipeline that is moving through key FDA and EMA milestones. How much of this move reflects changing sentiment rather than what the business is worth today?

Most Popular Narrative: 11% Undervalued

The most followed narrative currently values Scholar Rock Holding at a fair value of $59.31 compared with the last close at $52.92, which puts a spotlight on how much hinges on apitegromab and the wider neuromuscular pipeline.

Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline.

Read the complete narrative. Read the complete narrative.

Want to see what underpins that premium over the current share price? The narrative leans on aggressive revenue expansion, improving margins and a future earnings multiple that is far from ordinary. The specific mix of growth, profitability and discount rate assumptions is what really drives that $59.31 figure.

Result: Fair Value of $59.31 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Scholar Rock Holding’s story still hinges on apitegromab’s regulatory timing and commercial uptake, and higher 2025 operating expenses could keep losses elevated if launches slip.

Find out about the key risks to this Scholar Rock Holding narrative.

Next Steps

With both risks and rewards in focus for Scholar Rock Holding, it makes sense to move quickly and review the data yourself. To weigh those trade offs in detail, take a close look at the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Scholar Rock Holding?

Do not stop with a single stock story. Use the Simply Wall St screener to uncover other opportunities that could fit your goals just as well as Scholar Rock Holding.

• Target income potential by reviewing companies that meet the 8 dividend fortresses and see which payouts align with your expectations.
• Hunt for quality at a discount by scanning the screener containing 21 high quality undiscovered gems and spot companies that the market may be overlooking.
• Prioritise resilience by focusing on the 83 resilient stocks with low risk scores and compare businesses that show lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com